How does cannabis interact with pharmaceutical drugs?

Cannabis Life Network

Because of its broad range of effects, cannabis can cause a variety of interactions with pharmaceutical drugs. The post How does cannabis interact with pharmaceutical drugs? A drug interaction happens when two or more compounds come in contact with each other and create an effect.

More Women Switch Out Pharmaceuticals For Medical Marijuana

The Fresh Toast

More Women Switch Out Pharmaceuticals For Medical Marijuana. The post More Women Switch Out Pharmaceuticals For Medical Marijuana appeared first on The Fresh Toast. Medical Marijuana News Endometriosis gynecology menopause pharmaceuticals prescription drugs women

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ibere Pharmaceuticals Is The Quiet SPAC

Cannabis Law Report

While other cannabis industry SPAC’s have seemed to make big splashy entrances to the market, Ibere Pharmaceuticals quietly closed on… Read More. The post Ibere Pharmaceuticals Is The Quiet SPAC first appeared on Cannabis Law Report.

Corbus Pharmaceuticals Beats Estimates For Fourth Quarter

Cannabis Law Report

Endocannabinoid drug development company Corbus Pharmaceuticals Holdings, Inc. The post Corbus Pharmaceuticals Beats Estimates For Fourth Quarter appeared first on Cannabis Law Report. NASDAQ: CRBP) reported financial results for the fourth quarter and year-end 2020.…

Prohibition Publish 2nd Ed Of The Pharmaceutical Cannabis Report

Cannabis Law Report

In Europe, there is a clear trend towards the use of more precise formulations of unapproved cannabis products as well as pharmaceutical products. The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space.

MyMD Pharmaceuticals Schedules Business Update Conference Call

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing… Read More. Business Wire

Clever Leaves and Ethypharm Announce German Pharmaceutical Cannabis Partnership

Cannabis Law Report

Clever Leaves Partners with Leading European Pharmaceutical Company to Market EU-GMP Certified Medical Cannabis Products NEW YORK, March 17, 2021… Read More.

Jazz Pharmaceuticals Increases Guidance Based On GW Pharma Acquisition

Cannabis Law Report

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. The post Jazz Pharmaceuticals Increases Guidance Based On GW Pharma Acquisition appeared first on Green Market Report.

Cannabis vs. Pharmaceutical Medicine: One Not Very Surprising Study

Cannabis Law Report

Users are looking for safer alternatives to opioids, antidepressants, and arthritis relief. Green Entrepreneur

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. About MyMD Pharmaceuticals, Inc.

GW Pharmaceuticals loses $8 million over last quarter

Cannabis Law Report

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More.

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Cannabis Law Report

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed ex-GW Pharmaceuticals CFO… Read More.

Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

Cannabis Law Report

Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol “MYMD“ Upon… Read More. Business Wire

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Cannabis Law Report

Algernon Pharmaceuticals Inc. CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (“Algernon”), a clinical stage pharmaceutical development company, is pleased to announce… Read More.

Anebulo Pharmaceuticals Announces Pricing of Initial Public Offering

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Nasdaq: ANEB) (“Anebulo” or the “Company”), a clinical-stage biotechnology company developing novel solutions for people… Read More. Business Wire

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD is a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms.

February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 billion

Cannabis Law Report

The post February 4 2021: Jim Cramer on Jazz Pharmaceuticals buying GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV

Flora Growth Launches Cutting-Edge Global Cannabis Distribution Strategy, Implements Pharmaceutical Standards For Its Supply Chain

Cannabis Law Report

The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation.

February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 billion

Cannabis Law Report

The post February 4 2021: Jazz Pharmaceuticals buys GW Pharma for $7.2 … Read More. billion first appeared on Cannabis Law Report. Cannabis Law TV

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Jazz Pharmaceuticals Pick Up GW Pharma For A Cool $7.2 billion

Cannabis Law Report

The post Jazz Pharmaceuticals Pick Up GW Pharma For A Cool $7.2 For those of you living under a rock here is the news. We thought we better report it along with… Read More. billion first appeared on Cannabis Law Report. Breaking News

Prohibition Partners (UK) Publish “The Pharmaceutical Cannabis Report”

Cannabis Law Report

Here’s a quick blurb……… The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of … Read More.

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

About GW Pharmaceuticals Limited GW Pharmaceuticals (GW), a subsidiary of Jazz Pharmaceuticals plc, has established a world-leading position in cannabinoid science and medicine. GW was acquired by Jazz Pharmaceuticals in May 2021.

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

Cannabis Law Report

Poster presentation to address the preclinical cannabidiol derivative for the potential treatment of psychiatric disorders BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.

Article – Michael Sassano CEO and Chairman Somai Pharmaceuticals: GMP Series #5: ERP Implementations

Cannabis Law Report

Authors. Michael Sassano. When tackling your computer systems, software, and quality control processes, keep in mind. that there are many paths to travel, and the smartest way is to go piece by piece as your. company grows. You will find that there are diverse softwares for various sectors of your.

MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics

Cannabis Law Report

The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report.

Press Release: Psycheceutical, Inc. Announces New Patents that Enable Psychedelic Compounds to be Administered as Pharmaceutical Medicines

Cannabis Law Report

“Looking at the industry as it is growing, we are seeing the emergence of a brand-new sector: the psycheceutical industry, which merges the best of psychedelics and the best of pharmaceuticals.

Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

Cannabis Law Report

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. About Marinus Pharmaceuticals. Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Cannabis Law Report

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company”… Read More. Cannabis Finance News

Anebulo Pharmaceuticals to Participate in the Benzinga Cannabis Capital Conference in New York City

Cannabis Law Report

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. About Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc. Anebulo Pharmaceuticals, Inc.

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Exclusive Worldwide License Agreement with Canopy Growth Corporation for Key Pharmaceutical Assets

Cannabis Law Report

Under the terms of the agreement OCT will use reasonable efforts to develop and commercialise: (i) at least one CBD derivative; (ii) at least one CBG derivative; and (iii) at least one THC derivative, as pharmaceutical drug products. Oxford Cannabinoid Technologies Holdings plc. .

Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025 – Cannabis Business Executive

SpeedWeed

Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 The post Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025 – Cannabis Business Executive – Cannabis and Marijuana industry news.

MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21

Cannabis Law Report

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. About MyMD Pharmaceuticals, Inc.

GW Pharmaceuticals Wins the Queens Prize for Innovation

SpeedWeed

The British cannabis pharmaceutical company takes home an award that demonstrates how important cannabis has been to the British economy for over 20 years—but also how much it so far has been reserved, as an industry, and as a drug, for the elite. GW Pharmaceuticals was just awarded a so-called “ Queen’s Prize for Innovation.” . GW Pharmaceuticals in other words, may have just taken home a prestigious prize—and established itself as a global cannabis player.

Study Finds That Non-Pharmaceutical May Boost Quality Of Life Among Epilepsy Patients

Veriheal

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC.